» Articles » PMID: 38759096

The E592K Variant of SF3B1 Creates Unique RNA Missplicing and Associates with High-risk MDS Without Ring Sideroblasts

Abstract

Among the most common genetic alterations in myelodysplastic syndromes (MDS) are mutations in the spliceosome gene SF3B1. Such mutations induce specific RNA missplicing events, directly promote ring sideroblast (RS) formation, and generally associate with a more favorable prognosis. However, not all SF3B1 mutations are the same, and little is known about how distinct hotspots influence disease. Here, we report that the E592K variant of SF3B1 associates with high-risk disease features in MDS, including a lack of RS, increased myeloblasts, a distinct comutation pattern, and a lack of favorable survival seen with other SF3B1 mutations. Moreover, compared with other hot spot SF3B1 mutations, E592K induces a unique RNA missplicing pattern, retains an interaction with the splicing factor SUGP1, and preserves normal RNA splicing of the sideroblastic anemia genes TMEM14C and ABCB7. These data have implications for our understanding of the functional diversity of spliceosome mutations, as well as the pathobiology, classification, prognosis, and management of SF3B1-mutant MDS.

Citing Articles

SF3B1: from core splicing factor to oncogenic driver.

Bak-Gordon P, Manley J RNA. 2025; 31(3):314-332.

PMID: 39773890 PMC: 11874996. DOI: 10.1261/rna.080368.124.


Characterization of the SF3B1-SUGP1 interface reveals how numerous cancer mutations cause mRNA missplicing.

Zhang J, Xie J, Huang J, Liu X, Xu R, Tholen J Genes Dev. 2023; 37(21-24):968-983.

PMID: 37977822 PMC: 10760632. DOI: 10.1101/gad.351154.123.

References
1.
Inoue D, Chew G, Liu B, Michel B, Pangallo J, DAvino A . Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019; 574(7778):432-436. PMC: 6858563. DOI: 10.1038/s41586-019-1646-9. View

2.
Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R . Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64-9. DOI: 10.1038/nature10496. View

3.
Tanaka A, Nakano T, Nomura M, Yamazaki H, Bewersdorf J, Mulet-Lazaro R . Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. Blood. 2022; 140(8):875-888. PMC: 9412007. DOI: 10.1182/blood.2021015325. View

4.
Cretu C, Schmitzova J, Ponce-Salvatierra A, Dybkov O, De Laurentiis E, Sharma K . Molecular Architecture of SF3b and Structural Consequences of Its Cancer-Related Mutations. Mol Cell. 2016; 64(2):307-319. DOI: 10.1016/j.molcel.2016.08.036. View

5.
Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M . Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011; 118(26):6904-8. PMC: 3245210. DOI: 10.1182/blood-2011-08-373159. View